Journal: Cell reports

Article Title: Human Pluripotent Stem Cell-Derived Multipotent Vascular Progenitors of the Mesothelium Lineage Have Utility in Tissue Engineering and Repair

doi: 10.1016/j.celrep.2019.02.016

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: Rabbit Polyclonal anti-Flk1-1 , Acris Antibodies GmbH , Cat# AP02618PU-S; RRID: AB_1624459.

Techniques: Recombinant, Modification, DNA Methylation Assay, Flow Cytometry, Methylation, Software, Imaging, Cell Culture

Journal: Scientific Reports

Article Title: VEGFR2 alteration in Alzheimer’s disease

doi: 10.1038/s41598-017-18042-1

Figure Lengend Snippet: Analysis of sVEGFR1 and sVEGFR2 concentrations in plasma.

Article Snippet: Specific antibody to splicing variant form of VEGFR2 (sVEGFR2) was purchased from Acris Antibodies (Herford, Germany, AP26034PU-L).

Techniques:

Journal: Scientific Reports

Article Title: VEGFR2 alteration in Alzheimer’s disease

doi: 10.1038/s41598-017-18042-1

Figure Lengend Snippet: Analysis of VEGF, VEGF/sVEGFR1 and VEGF/sVEGFR2 in plasma.

Article Snippet: Specific antibody to splicing variant form of VEGFR2 (sVEGFR2) was purchased from Acris Antibodies (Herford, Germany, AP26034PU-L).

Techniques:

Journal: Scientific Reports

Article Title: VEGFR2 alteration in Alzheimer’s disease

doi: 10.1038/s41598-017-18042-1

Figure Lengend Snippet: Analysis of sVEGFR1 and sVEGFR2 concentrations in human plasma. Plasma sVEGFR1 and sVEGFR2 concentrations were measured by ELISA. The differences in the relative amounts of sVEGFR1 and sVEGFR2 were compared between dementia, MCI, and healthy controls by means of Mann-Whitney’s U-test within different groups. ( a ) Plasma sVEGFR1 levels in dementia subgroup were not closely correlated with VEGF-A ( r = −0.284, p = 0.013) ( b ) Plasma sVEGFR2 levels in dementia subgroup were significantly correlated with triglyceride ( r = 0.406, p = 0.0002).

Article Snippet: Specific antibody to splicing variant form of VEGFR2 (sVEGFR2) was purchased from Acris Antibodies (Herford, Germany, AP26034PU-L).

Techniques: Enzyme-linked Immunosorbent Assay

Journal: Scientific Reports

Article Title: VEGFR2 alteration in Alzheimer’s disease

doi: 10.1038/s41598-017-18042-1

Figure Lengend Snippet: ROC curve (AUC) of all the analyses with VEGF, sVEGFR1, and sVEGFR2 measured in the plasma.

Article Snippet: Specific antibody to splicing variant form of VEGFR2 (sVEGFR2) was purchased from Acris Antibodies (Herford, Germany, AP26034PU-L).

Techniques:

Journal: Scientific Reports

Article Title: VEGFR2 alteration in Alzheimer’s disease

doi: 10.1038/s41598-017-18042-1

Figure Lengend Snippet: sVEGFR2 and sVEGFR1 mRNA expression in endothelial cells. ( a ) HUVEC were treated with 10 μM of Aβ 1–40 peptides for 8 h. Real-time PCR results showing relative mRNA expression levels of VEGF-A , sVEGFR2 , and sVEGFR1 (n = 3). ( b ) After HUVEC were treated with 10 μM of Aβ 1–40 peptides for 24 h, sVEGFR1 and sVEGFR2 mRNA expression levels were measured by real-time PCR (n = 3). ( c ) HBMEC were treated with 10 μM of Aβ 1–40 peptides for 24 h. sVEGFR2 and sVEGFR1 mRNA expression levels were measured by real-time PCR (n = 3). ( d ) Splicing variant form of VEGFR2 (sVEGFR2) protein levels were detected in HBMEC cell culture media. The cropped blot is displayed in the main figure, and its full-length blot is presented in Supplementary Figure . Treatment of 10 μM of Aβ 1–40 peptides for 24 h decreased the sVEGFR2 levels (n = 3).

Article Snippet: Specific antibody to splicing variant form of VEGFR2 (sVEGFR2) was purchased from Acris Antibodies (Herford, Germany, AP26034PU-L).

Techniques: Expressing, Real-time Polymerase Chain Reaction, Variant Assay, Cell Culture

Journal: Scientific Reports

Article Title: VEGFR2 alteration in Alzheimer’s disease

doi: 10.1038/s41598-017-18042-1

Figure Lengend Snippet: VEGFR2 and VEGFR1 expression in endothelial cells. VEGFR2 ( a ) and VEGFR1 ( b ) expressions in the brain of 18-month-old wild type and APPsw/PS1ΔE9 transgenic mice were determined by immunoblot assay. The cropped blots are displayed in the main figures, and its full-length blots are presented in Supplementary Figure . Actin was used as a loading control. ( c ) After HUVEC were treated with 10 μM or 20 μM of Aβ 1–40 peptides for 24 h, VEGFR2 and VEGFR1 protein levels were measured by immunoblot assay. The cropped blots are displayed in the main figures, and its full-length blots are presented in Supplementary Figure . Actin was used as a loading control. ( d ) HUVEC were treated with 10 μM of Aβ 1–40 peptides for 8 h. Real-time PCR results showing relative mRNA expression levels of VEGFR2 and VEGFR1 (n = 3). NS = not significant.

Article Snippet: Specific antibody to splicing variant form of VEGFR2 (sVEGFR2) was purchased from Acris Antibodies (Herford, Germany, AP26034PU-L).

Techniques: Expressing, Transgenic Assay, Western Blot, Real-time Polymerase Chain Reaction

Journal: Scientific Reports

Article Title: VEGFR2 alteration in Alzheimer’s disease

doi: 10.1038/s41598-017-18042-1

Figure Lengend Snippet: Notch-1 and VEGFR2 mRNA expression in endothelial cells. ( a ) HUVEC were treated with 10 μM of Aβ 1–40 peptides for 8 h. Real-time PCR results showing relative mRNA expression levels of Notch-1 , TIMP-3 , CRP , CTGF , DKK-1 , and ADORA-2A (n = 3). ( b ) HUVEC were transiently transfected with the Notch intracellular domain (NICD) for 48 h. sVEGFR2 , VEGFR2 , sVEGFR1 , VEGFR1 , Hes-5 , and Hey-1 mRNA expression levels were measured by real-time PCR (n = 3). NS = not significant.

Article Snippet: Specific antibody to splicing variant form of VEGFR2 (sVEGFR2) was purchased from Acris Antibodies (Herford, Germany, AP26034PU-L).

Techniques: Expressing, Real-time Polymerase Chain Reaction, Transfection

Journal: Scientific Reports

Article Title: VEGFR2 alteration in Alzheimer’s disease

doi: 10.1038/s41598-017-18042-1

Figure Lengend Snippet: sVEGFR2 mRNA expression in human iPSC-derived neuronal cells. Relative sVEGFR2 mRNA expression levels were measured on human iPSC-derived neural progenitor stem cells from AD patient and healthy control (n = 3). Human iPSC cells were differentiated to neurons with treatment of neuronal differentiation media. sVEGFR2 mRNA expression was significantly decreased in human iPSC cells from AD patient ( p < 0.001).

Article Snippet: Specific antibody to splicing variant form of VEGFR2 (sVEGFR2) was purchased from Acris Antibodies (Herford, Germany, AP26034PU-L).

Techniques: Expressing, Derivative Assay

Journal: Journal of Neuroinflammation

Article Title: Succinate-induced macrophage polarization and RBP4 secretion promote vascular sprouting in ocular neovascularization

doi: 10.1186/s12974-023-02998-1

Figure Lengend Snippet: Effect of RBP4 on sprouting in vivo and in vitro. HUVECs were treated with 10 ng/ml RBP4 for 48 h, with or without 1 μM Ki8751 pretreatment for 12 h. A Relative mRNA expression of ANGPT2, TIE1, HEY1 and DLL4 in RBP4-treated HUVECs ( n = 3). B Relative mRNA expression of ANGPT2, TIE1, HEY1 and DLL4 in the control, RBP4 and RBP4 + Ki8751 groups ( n = 3). C , D Protein levels of VEGFR2 in the three groups ( n = 3). E Immunofluorescence staining of DAPI (blue) and VEGFR2 (red) in HUVECs. Scale bar: 50 μm. F Co-IP examination of VEGFR2-RBP4 interaction. H , J , K Retinal IB4 staining of P14 in OIR and relative number of tip cells as well as filopodia. Scale bar: 200 μm ( n = 3). G , I Choroidal sprouting analysis in three groups ( n = 3). Scale bar: 500 μm. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001

Article Snippet: Administration of the VEGFR2 inhibitor Ki8751 (1 μM for 12 h, #HY-12038, MCE) reduced VEGFR2 expression and attenuated RBP4 promotion of ANGPT2 and TIE1 as well as inhibition of HEY1 and DLL4 (Fig. B).

Techniques: In Vivo, In Vitro, Expressing, Control, Immunofluorescence, Staining, Co-Immunoprecipitation Assay